Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On Research Gate Missling likewise list only his university affiliation.
unfortunately, it looks like you will once again be wrong Georgejjl. But it was another good try.
Yah but the Chaikin Oscillator is heading lower!
The company also mentions a lot of things that doesn’t happen 😀, so who knows…only more time will tell.
and perhaps the MRHA given that a majority of patients were expected to enroll in the UK.
It seems to be an inference made from this PR Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) that assumes the CHMP is not involved until rapporteurs are assigned.
The EMA documents are quite convoluted in describing their own process and creates a market for consultants to assist. Typical of anything to do with public processes. Take for example (in my case) navigating product safety and ECM regulations and requirements - always a pain to deal with to feel certain all bases are covered in the just in case situation.
If A2-73 is ever approved for anything pricing it will be a good problem to have.
In that case expect the price to be much higher than your suggestions to date and be sold to far fewer patients than you imagine.
With no MAA filing this year $AVXL certainly would not look pretty.
The Chaikin Oscillator on a 3 months view hasn't substantially crossed zero to the positive since early July!
I'll go with Feb'ish or never - worked every time so far.
Hey Georgejjl, any closing price predications for today?
It is of course unfair, but my prediction from yesterday was and will remain completely correct. $AVXL can always be bought cheaper in the absence of substantial news.
Unfair because as an independent investor and commentator I can stay objective and post accordingly, as opposed to pumpers on a contract that stipulates positive posts only even when it flies in the face of logic.
There are some very imaginative minds posting on this mb.
Some will be eventually able to say “I told you so” and I am hoping that won’t be me with > 17% chance.
Appreciating that this slogan expresses an asymptotic function is probably important.
Indeed Sab, one would think Missling and Anavex should have got the message by now. Let's see, as always in some more time....
Already now we see of course that $AVXL can be had cheaper than when someone proudly announced having bought a few earlier today.
I expressed lots of positive things about $AVXL some years back before it became evident what we are dealing with. I will post positively again as soon as I perhaps see reason to do so. Let's say if for example if an MAA is filed and accepted by the CHMP, even if it doesn't happen until Feb'ish. At least then we are in with chance albeit less than <83%.
When it comes to $AVXL I have nor fear or uncertainty at all. Instead I have been completely objective and realistic taking profit at every irrational price spike big and small.
You do realise that Missling most likely knew how few patients completed the PDD trial at the time he made investors expect a peer reviewed publication on the trial data?
Why now? $AVXL will be much cheaper before perhaps that MAA is filed. Starting new trials and more drip feeding of more analysis of the P2b/3 AD trial at CTAD won't increase $AVXL imo.
But seriously though was it 2023 that was going to be the year of Anavex? Would you have an update to your profit and dividends $AVXL spreadsheet with the correct number of zeros added that you could share?
Even if EMA was on vacation what difference would it make, when Anavex still hasn’t filed an MAA and don’t expect to do so until sometime in Q4?
Or more likely Feb’s next year!
Hugely informative! I don't know how you do it, but it is quite amazing.
Expect $AVXL to close under $8 for ages.
Does it include the very long awaited expected PDD Peer reviewed paper and the rare disease trial that has remained undisclosed for how many years now?
The question remains, will $AVXL ever be a $8 stock again?
But how many angels are there on the head of that pin…
First motion to dismiss filed in the Blum v. Anavex Life Sciences Corporation (1:24-cv-01910) class action case. This will be important to watch, but hopefully the end of this litigation. Unfortunately the dockets have not been recapped just yet, so can't read the arguments for dismissal.
Surely A2-73 is then also an amyloid MoA as both drugs claims Autophagy.
There is a high dose arm in new n = 540 P2 Cognition Therapeutics trial with 200mg rather than the 300mg in the first trial.
Indeed and there was even dose dependency!
Try reading this slowly and carefully taking into account the bit I have marked in bold.
Why not just read the PR, poster and other material from the company to find out?
Perhaps it is counter to the Anavex only WGT thesis?
On the assumption, which some here adopt, that biotech companies always state fact and are not decorating or putting results in too optimistic wording - I would say that Cognition Therapeutics with their Sigma-2 antagonists seems fair competition to A2-73 with many MoA parallels incl. a claim to increase autophagy.
Yes 1 patient has a serious treatment related SAE, that it.
Well the pooled drug arm had significantly fewer SAE's than placebo all but one deemed not treatment related vs. the clear tolerability issues of A2-73, so I think you may be clutching at WGT straws there.
Interesting that CT1812 is a sigma-2 antagonist:
In so far as the Elayta results can be verified 39% reduction in decline is better than for A2-73, although that is most likely still to need a confirmatory trial. Also Cognition Therapeutics ran a proper RCT P2 Proof of Concent trial with n = 153 and over 182 days, unlike the far too small open label Anavex AD P2a trial.
Just give it a bit patience grasshopper.
Obviously the NHS is making space for A2-73 knowing full well that is has >83% chance of EMA approval and that they trust Georgejjl's price estimates. Infact the UK can just approve A2-73 completely independently, so one has to wonder why they didn't call Missling yet to tell him they want to approve with no further trials.
According to Georgejjl A2-73 actually prevents/cures COVID-19, so that's hard to imagine.